Life is too short!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Website looks real nice. MMEG
Hopefully these 007 guys are right. That would be big profit. EAPH
This one looks like it could hit .10 seriously. I'm holding won't miss up the chance. TXTM
Sorry for being so grumpy on Friday. EAPH
How can anyone possibly trust BETSD managements objectives after their track record. Buyer beware share selling diluted toxic company. I only lost 5k in 2016 but I also worked real hard for that $
Far from the truth. I won't be selling you my shares SORRY. EAPH
Big mistake smh. Sell .0018 if you can
I meant cats silly me EAPH news this week or next week.
Very very strong support over .03 keep your shares 1.+ on the horizon ;)
Wow so negative trying to talk people out of their 3 cent shares smh. Watch .25 by July :) ;)
Highly doubt this won't RS again. AZFL one of the biggest scams of all time.
BETSD forgot the D because of the RS. Don't be foolish in no way is that good news, their tracks record writes their story.
BETS = share selling scam
Shane put millions in his pockets off of shareholders what a POS BETS!
Trips then, Raise OS, then RS. never gonna be worth anything BETSD. Don't buy this garbage.
Wow BETSD growing into an even more POS Then it already was. Garbage share selling stock.
Don't sell your shares people, the hype is very real, and will happen EAPH ;)
The Legal Cannabis Market Maintains GrowthFont size: A | A | A
undefined undefined | Dow Jones
NEW YORK, March 24, 2017 /PRNewswire/ --
FinancialBuzz.com News Commentary
According to new data published Arcview Market Research, a leading publisher of cannabis market research, the legal cannabis market is projected to continue to grow at a 27 percent CAGR through 2021, despite conflicting signals from the current presidential administration. The report created by Arcview's data partner, BDS Analytics, points out that the two biggest drivers of growth in this industry are the passage and subsequent implementation of new adult-use laws and branded product subcategories. Examples of these subcategories would be vape cartridges, edibles, and other alternative consumption methods. Invictus MD Strategies Corporation (OTC: IVITF) (CSE: IMH.CN), Cannabis Science Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), Easton Pharmaceuticals Inc. (OTC: EAPH), CV Sciences Inc. (OTC: CVSI).
Troy Dayton, CEO of Arcview Market Research, said in a statement, "While the uncertainty created by the mixed signals coming out of the administration may cause a temporary dip in some valuations of cannabis companies and some more risk-averse institutional investors and multinational companies may continue to stay on the sidelines, it won't impact the growth of the market much at all. No matter what the administration does, states will continue to issue cannabis licenses to a long line of applicants and licensed cannabis outlets will continue to have long lines of consumers ready to purchase this product from regulated establishments."
Invictus MD Strategies Corporation (OTC: IVITF) (CSE: IMH.CN) is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"); Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.
Invictus MD Strategies Corp. this week announced, "that AB Laboratories Inc. (AB Labs) has successfully completed several test crops in its licensed production facility under the Access to ACMPR located in Hamilton, Ontario. The facility, which was licensed for cultivation under the ACMPR in October 2016, is currently operating at half capacity, with full production capacity scheduled by the end of May 2017. AB Labs has already received several direct inquiries from patients, which underscores the continuously growing demand."
Dan Kriznic, Chairman and CEO of Invictus MD, stated, "We are very pleased to see the speed at which AB Labs has been able to secure starter material, strains and potential offtake partners for production. In addition, considering the magnitude of AB Ventures' land acquisition and future facility, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, the combined production capacity of both AB Labs and AB Ventures is expected to exceed 20,000 kilograms in 2019. Invictus MD currently has approximately $15.5 million in cash and is fully funded for the initial expansion plans with AB Ventures. Construction plans are already underway and expect to be submitted to Health Canada by May 1, 2017."
Cannabis Science Inc. (OTC: CBIS) uses an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients' lives. The company announced the anticipated delivery of its very first pre-designed greenhouses with full tracking and reporting protocols to its California and Nevada operations. "Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed products readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage," stated CMO, Dr. Allen Herman.
Medical Marijuana Inc. (OTC: MJNA) announced that its major investment company, that is a leader in cannabinoid research and development, AXIM(R) Biotechnologies Inc., has retained the services of Ora(R), Inc., a global Contract Research Organization (CRO), to perform the company's upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world's leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases. "It is exciting to see AXIM start on pre-clinical efforts alongside esteemed ophthalmology professionals to develop a cannabinoid-based eye drop medication that may assist glaucoma sufferers," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "This partnership between AXIM and Ora is another new exciting milestone for AXIM's clinical development program, as it continues to move forward finding cannabinoid-based solutions for conditions for which there is no effective treatment."
Easton Pharmaceuticals Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The company has re-initiated discussions with Medicated Markets International LLC towards assets and relationships it has developed in California's Medical Marijuana industry and other jurisdictions throughout the world. With California and other States recent legalization of Medical Marijuana has opened up new opportunities for Easton Pharmaceuticals and its partners. Easton will continue to make the burgeoning medical marijuana, Vaporizer and e-liquids industry a priority and will continue to strive to be a big part of this sector moving forward.
CV Sciences Inc. (OTCQB: CVSI) is a life science company. The company operates in two segments: specialty pharmaceuticals and consumer products. CV Sciences' Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine, pursuing the approval of the U.S. Food and Drug Administration for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. CV Sciences' Consumer Products Division delivers botanical-based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider's offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician's recommendations.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real-time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated a total of seven thousand dollars for financial news dissemination and pr services by a third party non affiliate for invictus md strategies corporation. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information
(MORE TO FOLLOW) Dow Jones Newswires
March 24, 2017 09:00 ET (13:00 GMT)
When things start to materialize with EAPH I do think a lot of people will be sadly mistaken by the reality left chasing at a much higher PPS. Sounds to me like a few members on this board keep a pretty thorough updated due diligence to what the company is actually doing now, as well as a few that continue to daily criticize whether it's for their personal gain or that they're paid to do so. Nothing is guaranteed in the OTC market. Nothing here would surprise me either. With high risk comes high reward, along with the gamble of losing the money invested. I have checked EDGAR and personally feel that the company is as official as it gets. All this is my own opinion, do your own DD. Just remember EAPH could be a big player in the marijuana industry as well but time will tell all.
EAPH has been very active in 2017 I don't doubt for one second that the company is not ready to move forward. I think the next few months will be solid not only for EAPH, but also for shareholders. Patience pays big here IMO
Looks like the market is going to have a lot to digest. EAPH
EAPH is going to do some very big things this year 2017 IMO. If you look at the possibility's that might happen and will most likely will then we will be well above .03 I'm thinking very optimistic and absolutely believe the PR that have been released. I think in 6 months we could be trading well over $1.00
And the exclusive option to purchase up to 49% in a medical marijuana grow-op business/facility which has received a letter to build from health Canada. The company's gel formulation is thought to be an innovative and unique trans-dermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
EAPH headed for a much higher market value. I believe we start to see real progress with multiple PR's and 8k's. I also believe that the ibliss deal happens before the end of April. Strong support around .03 and more then likely a world of investors waiting for that ibliss 8k before jumping on board. Just remember the basic facts that EAPH deals in cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness, and other conditions that are all in various stages of development. The company has ventured into the potential lucrative medical marijuana industry through an investment into AMFIL Technologies, and their groZONE anti-bacterial system.
I hear you loud and clear. I will be watching closely on the field. For some reason though I just can't shake this good feeling that I have inside about EAPH. It could be to good to be true but then again what if it was all true. Not to speak on what it's but if that deal closes with guaranteed 15 mil revenues then EAPH will never look back at these prices IMHO. I'm not here to sell stock, I'm trying to catch a ride into the American dream. A place where my shares are selling on the S&P 500 anything is possible, and I will stay optimistic for a possible chance of a lifetime. I wish you well in your trading, and I will always be up for a good debate. Good night to you, and happy Friday morning to all :)
It's more then a story now, EAPH is a novel. I see it but will only believe with validated 8k's.
But you say most likely like there is a chance, who knows what the future holds. A 8k could come any day on a few things, and I surely want to be a part of the rise back to 2001 prices if it does. A number of things could have happened since 2001 like different management or even better yet the shares that were sold to accomplish where they are now. The past is yesterday, the future is tomorrow. Nobody on this board knows how the market will react if EAPH has come to closed deals and multi million dollar contracts.
Who knows a couple hundred dollars might make your ex-wifes money back in the next few months. EAPH looks to be building a brand name with real product.
So I'm guessing that you were invested some time around 2001 or 2002 and I completely understand your frustration with EAPH. I CLEARLY SEE A REVERSAL ON THAT CHART though.
I just don't see it, and last time I checked I had 20/20 vision ;) EAPH
Charts are showing me higher lows in 2017 which is a good sign don't you think? EAPH
Well I will trust and believe the PR's word over yours any day. No worries from me, as I will be here a while. EAPH
I beg to differ. If any substantial 8k's get released along with positive revenues in 2017 then EAPH will climb right out of the sewage IMO
I don't think there's anything to stress here as good things take time. EAPH
The information on this board is very real. Some have spoken with the company some might even work for the company. EAPH checks out on EDGAR, will most likely be up listed some time in 2018 IMO. Patience comes with high reward.
Looks like EAPH is doing some pretty big things but we still need some 8k's. Smart to buy at these levels IMO, foolish to sell.
If those deals are done then why don't you guys release the 8k's? EAPH
OWCP could very well be making over $100,000,000 gross annual income in a couple years. Think I just might not check my account for a couple years, and see what the value is then.
Loose over 5k and understand the dynamics of what AZFL truely is.
AZFL is a real OTC scam. Save your money.